View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2015	Nov. 16, 2015
Document And Entity Information [Abstract]
Document Type	10-Q/A
Amendment Flag	true
Amendment Description	This Amendment No. 1 on Form 10-Q/A (the “Form 10-Q/A”) to the Quarterly Report on Form 10-Q for TapImmune Inc. (“we” or the “Company”) for the quarterly period ended September 30, 2015, initially filed with the Securities and Exchange Commission (the “SEC”) on November 20, 2015 (the “Original Filing”), is being filed to restate accounting for the share purchase warrants and recording the fair value of the warrants under “Derivative liability- warrants” on its balance sheet with changes in the fair value over time reflected in the statements of operations as “Changes in fair value of derivative liabilities”. The restatement of the Company’s accounting for the share purchase warrants arose after a review by the Company’s management.As a result, the Board of Directors of the Company has determined that the Company’s previously issued consolidated unaudited financial statements and reports filed with the SEC for the quarterly period ended September 30, 2015 should not be relied upon. For a more detailed description of the effects of the restatement, see further discussion in Note 1A, “Amendment to Previously Reported Quarterly Financial Statements” to our consolidated financial statements included in Part I, Item 1 of this report.For the convenience of the reader, this Form 10-Q/A sets forth the Original Filings in their entirety. However, this Form 10-Q/A only amends and restates Items 1 and 2 of Part I of the Original Filing, in each case, solely as a result of, and to reflect, the restatement, and no other information in the Original Filing is amended hereby. The foregoing items have not been updated to reflect other events occurring after the Original Filings or to modify or update those disclosures affected by subsequent events. In addition, pursuant to the rules of the SEC, Item 6 of Part II of the Original Filings has been amended to contain currently dated certifications from the Company’s Chief Executive Officer and Chief Financial Officer, as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, and are attached as Exhibits 31.1 and 32.1 to this report. We have also updated our financial statements formatted in Extensible Business Reporting Language (XBRL) in Exhibits 101.Except for the foregoing amended information, this Form 10-Q/A continues to speak as of the dates of the Original Filings, and the Company has not updated the disclosures contained herein to reflect events that occurred at a later date. Other events occurring after the filings of the Original Filings or other disclosures necessary to reflect subsequent events will be addressed in any reports filed with the SEC subsequent to the date of this filing.
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Trading Symbol	TPIV
Entity Registrant Name	TAPIMMUNE INC.
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		64,618,762

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Current Assets
Cash	$ 6,087,016	$ 141,944	$ 613,645	$ 48,589
Prepaid expenses and deposits	138,286	82,504
Total Current Assets	6,225,302	224,448
Current Liabilities
Accounts payable and accrued liabilities	874,628	693,362
Research agreement obligations	492,365	492,365
Derivative liability - warrants	32,196,000	9,415
Promissory notes	52,942	52,942
Total Current Liabilities	33,615,935	1,248,084
Stockholders' Equity
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Common stock, $0.001 par value, 500,000,000 shares authorized 62,890,763 shares issued and outstanding (2014 - 20,318,815)	62,891	20,319
Additional paid-in capital	104,402,206	85,265,776
Accumulated deficit	(131,855,730)	(86,309,731)
Total Stockholders' Deficit	(27,390,633)	(1,023,636)
Total LIABILITIES AND STOCKHOLDERS' DEFICIT	6,225,302	224,448
Series A Preferred Stock [Member]
Stockholders' Equity
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Series B Preferred Stock [Member]
Stockholders' Equity
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Convertible preferred stock	$ 10,000,000	$ 10,000,000
Preferred stock par value	$ 0.001	$ 0.001
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	62,890,763	20,318,815
Common stock shares outstanding	62,890,763	20,318,815
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating expenses:
General and administrative	$ 968,759	$ 1,351,209	$ 2,324,432	$ 2,899,181
Research and development	769,219	32,500	1,579,754	77,500
Total Operating expense	1,737,978	1,383,709	3,904,186	2,976,681
Loss from Operations	(1,737,978)	(1,383,709)	(3,904,186)	(2,976,681)
Other Income (Expense)
Foreign exchange gain			775
Changes in fair value of derivative liabilities	30,266,000	(74,062)	(28,485,585)	243,475
Accretion of interest on convertible debt				(492,296)
Interest and finance charges		(15,425)		(83,247)
Shares issued in settlement agreement	(24,697)		(24,697)
Loss on settlement of debt		(94,640)		(26,837,837)
Net Income (Loss) for the Period	28,503,325	(1,567,836)	(32,413,693)	(30,146,586)
Other comprehensive income (loss)
Foreign exchange translation adjustment	0	2,972	0	2,765
TOTAL COMPREHENSIVE INCOME (LOSS)	$ 28,503,325	$ (1,564,864)	$ (32,413,693)	$ (30,143,821)
Basic Net Income (Loss) per Share	$ 0.59	$ (0.09)	$ (0.88)	$ (2.27)
Diluted Net Income (Loss) per Share	$ 0.35	$ (0.09)	$ (0.88)	$ (2.27)
Weighted Average Number of Common Shares Outstanding, Basic	48,585,003	17,310,708	36,651,565	13,292,886
Weighted Average Number of Common Shares Outstanding, Diluted	80,944,993	17,310,708	36,651,565	13,292,886

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) AS RESTATED - 9 months ended Sep. 30, 2015 - USD ($)	Total	Common Stock	Additional Paid-In Capital	Retained Earnings / Accumulated Deficit
Balance, Share at Dec. 31, 2014		20,318,816
Balance at Dec. 31, 2014	$ (1,023,636)	$ 20,319	$ 85,265,776	$ (86,309,731)
Accounts payable settled in shares		118,450
Accounts payable settled in Amount	21,913	$ 118	21,795
Private placement (net of finders' fee of $140,000), shares		12,363,447
Private placement (net of finders' fee of $140,000)	2,326,015	$ 12,321	2,313,694
Fair value of derivative	(9,313,000)		(2,313,694)	(6,999,306)
Fair value of warrants issued on May 28, 2015	(6,133,000)			(6,133,000)
Exercise of warrants, Share		29,639,990
Exercise of warrants, Amount	7,427,998	$ 29,682	7,398,316
Reclassification of derivative liabilities to equity at exercise date	11,745,000		11,745,000
Finders' fee on exercise of warrants	(316,508)		(316,508)
Shares issued in settlement agreement, Shares		49,950
Shares issued in settlement agreement, Amount	26,473	$ 50	26,423
Stock- based compensation, Share		400,110
Stock- based compensation, Amount	261,805	$ 401	261,404
Net loss	(32,413,693)			(32,413,693)
Ending Balance, Shares at Sep. 30, 2015		62,890,763
Ending Balance at Sep. 30, 2015	$ (27,390,633)	$ 62,891	$ 104,402,206	$ (131,855,730)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (32,413,693)	$ (30,146,586)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities	28,485,585	(243,475)
Loss on settlement of debt		26,837,837
Loss on settlement agreement	24,697
Accretion of interest on convertible debt		492,296
Share-based compensation	261,805	1,265,625
Changes in operating assets and liabilities:
Prepaid expenses and deposits	(55,782)	(15,000)
Accounts payable and accrued liabilities	204,956	291,359
NET CASH USED IN OPERATING ACTIVITIES	(3,492,432)	(1,517,944)
CASH FLOWS FROM FINANCING ACTIVITIES
Private placement, net of finders' fee	2,326,014	2,097,500
Proceeds from loans payable	7,427,998
Finders' fee on exercise of warrants	(316,508)	500
Repayment of promissory notes		(15,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES	9,437,504	2,083,000
INCREASE IN CASH	5,945,072	565,056
CASH, BEGINNING OF PERIOD	141,944	48,589
CASH, END OF PERIOD	6,087,016	613,645
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES
Accounts payable settled in common stock	24,000	683,000
Fair value of issuance of warrants in January and March 2015 financing	9,313,000
Issuance of additional warrants in May 28, 2015 transaction	6,133,000
Reclassification of derivative warrant liabilities to equity at exercise date	$ 11,745,000
Conversion of debt obligations into common stock:
Accrued interest		476,000
Convertible notes payable		3,797,000
Loans payable, related party		42,000
Promissory notes, related party		210,000
Due to related parties		369,000
Fair value derivative liability - conversion option at conversion		$ 708,000

AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS

NOTE 1A: AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS

The Company’s previously issued consolidated financial statements for the three and nine months ended September 30, 2015 have been restated related to the Company’s accounting for share purchase warrants issued as part of two registered transactions in January 2015 and March 2015. Previously, the fair value of certain series of the share purchase warrants (Series B, B-1, C, C-1, D, D-1, E and E-1) was concluded by management to be classified within stockholders’ equity (deficit). The Company has reviewed the terms and conditions underlying its outstanding share purchase warrants and determined that the accounting for certain series of the warrants should be amended.

Management reviewed ASC 480-10 Distinguishing liabilities from equity and ASC 815-40 Contracts in an Entity’s Own Equity to arrive at this conclusion that the common stock purchase warrants should be classified as a liability, not equity, as the Company cannot control their ability to gross settle the financial instruments with registered securities.

The Company has restated its accounting for certain series of the share purchase warrants and recorded the fair value of the warrants under “Derivative liability- warrants” on its balance sheet with changes in the fair value over time reflected in the statements of operations as “Changes in fair value of derivative liabilities”.

As a result of these adjustments, net income for the three months ended September 30, 2015 was increased by $26,019,000 and net loss for the nine months ended September 30, 2015 was increased by $15,470,000. The Company has reported an amended net income of $28,503,000 versus the previously reported net income of approximately $2,484,000 for the three months ended September 30, 2015 and an amended net loss of $32,414,000 versus the previously reported net loss of approximately $16,943,000 for the nine months ended September 30, 2015.

The following table summarizes the effect of the restatement on the consolidated statement of operations for the three and nine months ended September 30, 2015:

TAPIMMUNE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	September 30, 2015 (Unaudited)
	As Previously Reported			Adjustments			As Restated
ASSETS
Current Assets
Cash		6,087,016			—			6,087,016
Prepaid expenses and deposits		138,286			—			138,286

		6,225,302			—			6,225,302

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities		874,628			—			874,628
Research agreement obligations		492,365			—			492,365
Derivative liability – warrants		7,426,684			24,769,316			32,196,000
Promissory notes		52,942			—			52,942

		8,846,619			24,769,316			33,615,935

COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)
Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized:
Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 – 20,318,815)		62,891			—			62,891
Additional paid-in capital		100,568,900			3,833,306			104,402,206
Accumulated deficit		(103,253,108	)		(28,602,622	)		(131,855,730	)

		(2,621,317	)		(24,769,316	)		(27,390,633	)

		6,225,302			—			6,225,302

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Three Months Ended September 30, 2015
	As Previously Reported			Adjustments		As Restated
Operating expenses:
General and administrative		968,759			—		968,759
Research and development		769,219			—		769,219

Loss from Operations		(1,737,978	)		—		(1,737,978	)
Other Income (Expense)
Changes in fair value of derivative liabilities		4,246,663			26,019,337		30,266,000
Foreign exchange		—			—		—
Inducement expense		—
Shares issued in settlement agreement		(24,697	)		—		(24,697	)

Net income (loss) for the Period		2,483,988			26,019,337		28,503,325

Other comprehensive income
Foreign exchange translation adjustment		—			—		—

TOTAL COMPREHENSIVE INCOME (LOSS)		2,483,988			26,019,337		28,503,325

Basic Net Income (Loss) per Share		0.05			0.54		0.59
Diluted Net Income (Loss) per Share		0.03			0.32		0.35

Weighted Average Number of
Common Shares Outstanding, Basic		48,585,003			48,585,003		48,585,003

Weighted Average Number of
Common Shares Outstanding, Diluted		80,944,993			80,944,993		80,944,993

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Nine Months Ended September 30, 2015
	As Previously Reported			Adjustments			As Restated
Operating expenses:
General and administrative		2,324,432			—			2,324,432
Research and development		1,579,754			—			1,579,754

Loss from Operations		(3,904,186	)		—			(3,904,186	)
Other Income (Expense)
Changes in fair value of derivative liabilities		(4,759,269	)		(23,726,316	)		(28,485,585	)
Foreign exchange		775			—			775
Inducement expense		(8,256,000	)		8,256,000			—
Shares issued in settlement agreement		(24,697	)		—			(24,697	)

Net income (loss) for the Period		(16,943,377	)		(15,470,316	)		(32,413,693	)

Other comprehensive income
Foreign exchange translation adjustment		—			—			—

TOTAL COMPREHENSIVE INCOME (LOSS)		(16,943,377	)		(15,470,316	)		(32,413,693	)

Basic Net Income (Loss) per Share		(0.46	)		(0.42	)		(0.88	)
Diluted Net Income (Loss) per Share		(0.46	)		(0.42	)		(0.88	)

Weighted Average Number of
Common Shares Outstanding, Basic		36,651,565			36,651,565			36,651,565

Weighted Average Number of
Common Shares Outstanding, Diluted		36,651,565			36,651,565			36,651,565

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Nine Months Ended September 30, 2015
	As Previously Reported			Adjustments			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(16,943,377	)		(15,470,316	)		(32,413,693	)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities		4,759,269			23,726,316			28,485,585
Inducement expense		8,256,000			(8,256,000	)		—
Loss on settlement agreement		24,697			—			24,697
Stock based compensation		261,805			—			261,805
Changes in operating assets and liabilities:
Prepaid expenses		(55,782	)		—			(55,782	)
Accounts payable and accrued liabilities		204,956			—			204,956

NET CASH USED IN OPERATING ACTIVITIES		(3,492,432	)		—			(3,492,432	)

CASH FLOWS FROM FINANCING ACTIVITIES
Private placement, net of finders’ fee		2,009,506			316,508			2,326,014
Proceeds from exercise of warrants		7,427,998			—			7,427,998
Finders’ fee on exercise of warrants		—			(316,508	)		(316,508	)

NET CASH PROVIDED BY FINANCING ACTIVITIES		9,437,504			—			9,437,504

INCREASE IN CASH		5,945,072			—			5,945,072
CASH, BEGINNING OF PERIOD		141,944			—			141,944

CASH, END OF PERIOD		6,087,016			—			6,087,016

NET INCOME (LOSS) PER SHARE, AS RESTATED

9 Months Ended

Sep. 30, 2015

Noncontrolling Interest [Abstract]

NET INCOME (LOSS) PER SHARE, AS RESTATED

NOTE 5: NET INCOME (LOSS) PER SHARE, AS RESTATED

Basic income (loss) per common share is computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted income per common share is computed similar to basic income per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following table sets forth the computation of income (loss) per share:


	For the Three Months Ended September 30,					For the Nine Months Ended September 30,
	2015		2014			2015			2014
Net income (loss)	$	28,503,325	$	(1,567,836	)	$	(32,413,693	)	$	(30,146,586	)
Weighted average shares outstanding - basic		48,585,003		17,310,708			36,651,565			13,292,886
Common stock warrants		31,959,990		—			—			—
Common stock options		400,000		—			—			—

Weighted average shares outstanding - diluted		80,944,993		17,310,708			36,651,565			13,292,886

Net income (loss) per share data:
Basic	$	0.59	$	(0.09	)	$	(0.88	)	$	(2.27	)
Diluted	$	0.35	$	(0.09	)	$	(0.88	)	$	(2.27	)

Options, warrants, and convertible debt outstanding were all considered anti-dilutive for the nine months ended September 30, 2015 and 2014, due to net losses.

The following securities were not included in the diluted net loss per share calculation because their effect was anti-dilutive as of the periods presented:


	Nine Months Ended September 30,
	2015		2014
Common stock options		465,000		65,000
Common stock warrants - equity treatment		2,531,000		185,000
Common stock warrants - liability treatment		56,998,000		49,000
Convertible notes		—		7,000

Potentially dilutive securities		59,994,000		306,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION, AS RESTATED

9 Months Ended

Sep. 30, 2015

Text Block [Abstract]

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION, AS RESTATED

NOTE 6: DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY – CONVERSION OPTION, AS RESTATED

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy for the nine months ended 2015 and 2014 is as follows:


Stock Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Nine Months Ending September 30, 2015			For the Nine Months Ending September 30, 2014
Strike price	$	0.63		$	5.84
Volatility (annual)		159	%		156.00	%
Risk-free rate		1.4	%		1.07	%
Contractual term (years)		4.5			3.33
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:


	As of September 30, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	32,196,000		—		—	$	32,196,000	$	32,196,000

Total	$	32,196,000		—		—	$	32,196,000	$	32,196,000


	As of December 31, 2014
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		—		—	$	9,000	$	9,000

Total	$	9,000		—		—	$	9,000	$	9,000

There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2015.

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2015:


	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the period		15,446,000
Exercise of warrants		(11,745,000	)
Change in fair value of warrant liability		28,486,000

Balance – September 30, 2015	$	32,196,000

The valuation of warrants is subjective and is affected by changes in inputs to the valuation model including the price per share of common stock, the historical volatility of the stock price, risk-free rates based on U.S. Treasury security yields, the expected term of the warrants and dividend yield. Changes in these assumptions can materially affect the fair value estimate. The Company could ultimately incur amounts to settle the warrant at a cash settlement value that is significantly different than the carrying value of the liability on the financial statements. The Company will continue to classify the fair value of the warrants as a liability until the warrants are exercised, expire, or are amended in a way that would no longer require these warrants to be classified as a liability. Changes in the fair value of the common stock warrants liability are recognized as a component of other income (expense) in the Statements of Operations.

During 2014 the Company entered into numerous extinguishment agreements with various convertible note holders. As a result the derivative liability associated with the bifurcated conversion options were extinguished at the date of conversion and recorded in the loss on extinguishment in the Statement of Operations. The inputs utilized in the final mark to market were as follows:


Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending September 30, 2015			For the Quarter Ending September 30, 2014
Strike price	$	—		$	1.03
Volatility (annual)		—	%		199.00	%
Risk-free rate		—	%		0.05	%
Contractual term (years)		—			0.24
Dividend yield (per share)		—	%		—	%

Fair value of Conversion Option at extinguishment	$	—		$	708,000

CAPITAL STOCK, AS RESTATED

9 Months Ended

Sep. 30, 2015

Text Block [Abstract]

CAPITAL STOCK, AS RESTATED

NOTE 8: CAPITAL STOCK, AS RESTATED

2015 Share Transactions

Private placements

In January, 2015, the Company entered into a Securities Purchase Agreement with certain investors for the sale of 7,320,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $1,250,000, net of finders’ fee and offering expenses of approximately $214,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “January 2015 Warrants”). Series A warrants are exercisable at $1.50 per share, with a five year term. Series B warrants are exercisable at $0.40 per share, with a six month term. Series C warrants are exercisable at $1.00 per share, with a five year term. Series D warrants are exercisable at $0.75 per share only if and to the extent that the Series B warrants are exercised, with a five year term from the date that the Series B warrants are exercised. Series E warrants are exercisable at $1.25 per share, only if and to the extent that the Series C warrants are exercised, with a five year term from the date that the Series C warrants are exercised.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 366,000 common shares with substantially the same terms as the January 2015 Warrants.

In March, 2015, the Company entered into a Securities Purchase Agreement with certain accredited investors for the sale of 5,000,000 units at a purchase price of $0.20 per unit, for a total purchase price of approximately $950,000, net of finders’ fee and offering expenses of approximately $50,000. Each unit consisting of (i) one share of the Company’s Common Stock, (ii) one Series A warrant to purchase one share of common stock, (iii) one Series B warrant to purchase one share of common stock (iv) one Series C warrant to purchase one share of common stock, (v) one Series D warrant to purchase one share of common stock, and (vi) one Series E warrant to purchase one share of common stock (the Series A, B, C, D and E warrants are hereby collectively referred to as the “March 2015 Warrants”). The March 2015 Warrants have substantially the same terms as the January 2015 Warrants.

Pursuant to a placement agent agreement, the Company agreed to issue warrants to purchase 125,000 common shares with substantially the same terms as the March 2015 Warrants.

Initial Fair Value of Warrants Issued

Pursuant to ASC 480-10 Distinguishing liabilities from equity and ASC 815-40 Contracts in an Entity’s Own Equity, the common stock purchase warrants are classified as a derivative liability as the Company cannot control their ability to gross settle the financial instruments with registered securities. The fair value of the warrants issued pursuant to the January and March 2015 stock purchase agreement was $9,313,000. The weighted average inputs include contractual term of 5.0 years, volatility of 158% and risk free rate of 1.2%.

May 2015 Restructuring agreement

In May 2015, the Company entered into a restructuring agreement with the investors of the January 2015 and March 2015 private placements, where:

•

The exercise price of the Series A warrants was changed from $1.50 per warrant to $0.10 per warrant,

•

The exercise price of Series B warrants was changed from $0.40 per warrant to $0.20 per warrant,

•

Each warrant of Series B existing prior to the restructuring agreement was replaced with two warrants of such series,

•

The exercise price of the Series C warrants was changed from $1.00 per warrant to $0.50 per warrant, and

•

Each warrant of Series C existing prior to the restructuring agreement was replaced with two warrants of such series.

As a result of the restructuring agreement, the Company issued an additional 12,320,000 Series B warrants and 12,320,000 Series C Warrants. The fair value of the warrants issued pursuant to the May 2015 restructuring agreement was $6,133,000. The weighted average inputs include contractual term of 2.46 years, volatility of 141% and risk free rate of 1.5%.

Share Purchase Warrants

During the nine months ended September 30, 2015, a warrant holder exercised 5,000,000 of Series C warrants at $0.50 per warrant for a total of $2,500,000.

During the nine months ended September 30, 2015, warrant holders exercised 24,639,995 of Series B warrants at $0.20 per warrant for a total of $4,928,000.

A summary of the Company’s share purchase warrants as of September 30, 2015 and changes during the period is presented below:


	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		86,730,975			0.54		4.52
Exercised		(29,639,995	)		0.25		—
Extinguished or expired		(203,900	)		2.39		—

Balance, September 30, 2015		59,546,497		$	0.68		4.47

Stock Compensation Plan

On October 14, 2009, the Company adopted the 2009 Stock Incentive Plan (the “2009 Plan”) which supersedes and replaces the 2007 Stock Plan. The 2009 Plan allows for the issuance of up to 10,000,000 common shares. Options granted under the Plan shall be at prices and for terms as determined by the Board of Directors.

During the nine months ended September 30, 2015 the Company granted 400,000 stock options with a weighted average exercise price of $0.17. The fair value of the options was estimated to be $62,000 or $0.16. The weighted average inputs used to value the options were an expected life of 5 years, volatility of 155%, risk-free interest rate of 1.54% and dividend yield of 0%.

Stock based compensation costs of $21,000 are expected to be recognized over the next 1.4 years.

In July, 2015, the Company issued 118,450 shares of common stock with a fair value of $21,913 to its counsel for legal services rendered through January 21, 2015.

In August, 2015, the Company issued 50,000 shares of common stock with fair value of $26,474 as full settlement to a marketing consultant for services provided to the Company in 2014 and 2015.

Share purchase options

A summary of the Company’s stock options as of September 30, 2015 and changes during the period is presented below:


	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life		Intrinsic Value
Outstanding at January 1, 2014		65,430		18.00		5.04	$	—
Issued		—		—		—		—
Cancelled/Forfeited		—		—		—		—

Outstanding at January 1, 2015		65,430		18.00		4.04		—
Issued		400,000		0.17		4.39	$	182,000

Outstanding at September 30, 2015		465,430	$	2.62		4.23	$	182,000

Exercisable at September 30, 2015		238,810	$	5.00		4.09	$	80,000

A summary of the status of the Company’s unvested options as of September 30, 2015 is presented below:


	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested, December 31, 2014		278		$	18.00
Granted		400,000			0.16
Vested		(173,658	)		0.21
Cancelled		—			—

Unvested, September 30, 2015		226,620		$	0.16

AMENDMENT TO PREVIOUSLY REPORTED QUARTERLY FINANCIAL STATEMENTS (Tables)

9 Months Ended

Sep. 30, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Restatement of The Company's Consolidated Statements

The following table summarizes the effect of the restatement on the consolidated statement of operations for the three and nine months ended September 30, 2015:

TAPIMMUNE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


	September 30, 2015 (Unaudited)
	As Previously Reported			Adjustments			As Restated
ASSETS
Current Assets
Cash		6,087,016			—			6,087,016
Prepaid expenses and deposits		138,286			—			138,286

		6,225,302			—			6,225,302

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current Liabilities
Accounts payable and accrued liabilities		874,628			—			874,628
Research agreement obligations		492,365			—			492,365
Derivative liability – warrants		7,426,684			24,769,316			32,196,000
Promissory notes		52,942			—			52,942

		8,846,619			24,769,316			33,615,935

COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity (Deficit)
Convertible preferred stock, $0.001 par value — 10,000,000 shares authorized:
Series A, $0.001 par value, 1,250,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Series B, $0.001 par value, 1,500,000 shares designated, -0- shares issued and outstanding as of March 31, 2015 and December 31, 2014		—			—			—
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 – 20,318,815)		62,891			—			62,891
Additional paid-in capital		100,568,900			3,833,306			104,402,206
Accumulated deficit		(103,253,108	)		(28,602,622	)		(131,855,730	)

		(2,621,317	)		(24,769,316	)		(27,390,633	)

		6,225,302			—			6,225,302

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Three Months Ended September 30, 2015
	As Previously Reported			Adjustments		As Restated
Operating expenses:
General and administrative		968,759			—		968,759
Research and development		769,219			—		769,219

Loss from Operations		(1,737,978	)		—		(1,737,978	)
Other Income (Expense)
Changes in fair value of derivative liabilities		4,246,663			26,019,337		30,266,000
Foreign exchange		—			—		—
Inducement expense		—
Shares issued in settlement agreement		(24,697	)		—		(24,697	)

Net income (loss) for the Period		2,483,988			26,019,337		28,503,325

Other comprehensive income
Foreign exchange translation adjustment		—			—		—

TOTAL COMPREHENSIVE INCOME (LOSS)		2,483,988			26,019,337		28,503,325

Basic Net Income (Loss) per Share		0.05			0.54		0.59
Diluted Net Income (Loss) per Share		0.03			0.32		0.35

Weighted Average Number of
Common Shares Outstanding, Basic		48,585,003			48,585,003		48,585,003

Weighted Average Number of
Common Shares Outstanding, Diluted		80,944,993			80,944,993		80,944,993

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)


	Nine Months Ended September 30, 2015
	As Previously Reported			Adjustments			As Restated
Operating expenses:
General and administrative		2,324,432			—			2,324,432
Research and development		1,579,754			—			1,579,754

Loss from Operations		(3,904,186	)		—			(3,904,186	)
Other Income (Expense)
Changes in fair value of derivative liabilities		(4,759,269	)		(23,726,316	)		(28,485,585	)
Foreign exchange		775			—			775
Inducement expense		(8,256,000	)		8,256,000			—
Shares issued in settlement agreement		(24,697	)		—			(24,697	)

Net income (loss) for the Period		(16,943,377	)		(15,470,316	)		(32,413,693	)

Other comprehensive income
Foreign exchange translation adjustment		—			—			—

TOTAL COMPREHENSIVE INCOME (LOSS)		(16,943,377	)		(15,470,316	)		(32,413,693	)

Basic Net Income (Loss) per Share		(0.46	)		(0.42	)		(0.88	)
Diluted Net Income (Loss) per Share		(0.46	)		(0.42	)		(0.88	)

Weighted Average Number of
Common Shares Outstanding, Basic		36,651,565			36,651,565			36,651,565

Weighted Average Number of
Common Shares Outstanding, Diluted		36,651,565			36,651,565			36,651,565

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)


	Nine Months Ended September 30, 2015
	As Previously Reported			Adjustments			As Restated
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss		(16,943,377	)		(15,470,316	)		(32,413,693	)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities		4,759,269			23,726,316			28,485,585
Inducement expense		8,256,000			(8,256,000	)		—
Loss on settlement agreement		24,697			—			24,697
Stock based compensation		261,805			—			261,805
Changes in operating assets and liabilities:
Prepaid expenses		(55,782	)		—			(55,782	)
Accounts payable and accrued liabilities		204,956			—			204,956

NET CASH USED IN OPERATING ACTIVITIES		(3,492,432	)		—			(3,492,432	)

CASH FLOWS FROM FINANCING ACTIVITIES
Private placement, net of finders’ fee		2,009,506			316,508			2,326,014
Proceeds from exercise of warrants		7,427,998			—			7,427,998
Finders’ fee on exercise of warrants		—			(316,508	)		(316,508	)

NET CASH PROVIDED BY FINANCING ACTIVITIES		9,437,504			—			9,437,504

INCREASE IN CASH		5,945,072			—			5,945,072
CASH, BEGINNING OF PERIOD		141,944			—			141,944

CASH, END OF PERIOD		6,087,016			—			6,087,016

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION, AS RESTATED (Tables)

9 Months Ended

Sep. 30, 2015

Text Block [Abstract]

Valuation methodology


Stock Purchase Warrants	Weighted Average Inputs for the Period
Date of valuation	For the Nine Months Ending September 30, 2015			For the Nine Months Ending September 30, 2014
Strike price	$	0.63		$	5.84
Volatility (annual)		159	%		156.00	%
Risk-free rate		1.4	%		1.07	%
Contractual term (years)		4.5			3.33
Dividend yield (per share)		0	%		0	%

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Derivative liability – warrants:


	As of September 30, 2015
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	32,196,000		—		—	$	32,196,000	$	32,196,000

Total	$	32,196,000		—		—	$	32,196,000	$	32,196,000


	As of December 31, 2014
	Fair Value Measurements
	Fair Value		Level 1		Level 2		Level 3		Total
Derivative liability - warrants	$	9,000		—		—	$	9,000	$	9,000

Total	$	9,000		—		—	$	9,000	$	9,000

Measured at fair value

There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2015.

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2015:


	Derivative liability – warrants
Balance – December 31, 2014	$	9,000
Additions during the period		15,446,000
Exercise of warrants		(11,745,000	)
Change in fair value of warrant liability		28,486,000

Balance – September 30, 2015	$	32,196,000

Numerous extinguishment agreements


Conversion Option	Weighted Average Inputs for the Period
Date of valuation	For the Quarter Ending September 30, 2015			For the Quarter Ending September 30, 2014
Strike price	$	—		$	1.03
Volatility (annual)		—	%		199.00	%
Risk-free rate		—	%		0.05	%
Contractual term (years)		—			0.24
Dividend yield (per share)		—	%		—	%

Fair value of Conversion Option at extinguishment	$	—		$	708,000

CAPITAL STOCK, AS RESTATED (Tables)

9 Months Ended

Sep. 30, 2015

Text Block [Abstract]

Share Purchase Warrants

A summary of the Company’s share purchase warrants as of September 30, 2015 and changes during the period is presented below:


	Number of Warrants			Weighted Average Exercise Price		Weighted Average Remaining Life
Balance, December 31, 2014		2,659,417			1.83		4.15
Issued		86,730,975			0.54		4.52
Exercised		(29,639,995	)		0.25		—
Extinguished or expired		(203,900	)		2.39		—

Balance, September 30, 2015		59,546,497		$	0.68		4.47

Share purchase options

Share purchase options

A summary of the Company’s stock options as of September 30, 2015 and changes during the period is presented below:


	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Life		Intrinsic Value
Outstanding at January 1, 2014		65,430		18.00		5.04	$	—
Issued		—		—		—		—
Cancelled/Forfeited		—		—		—		—

Outstanding at January 1, 2015		65,430		18.00		4.04		—
Issued		400,000		0.17		4.39	$	182,000

Outstanding at September 30, 2015		465,430	$	2.62		4.23	$	182,000

Exercisable at September 30, 2015		238,810	$	5.00		4.09	$	80,000

A summary of the status of the Company’s unvested options as of September 30, 2015 is presented below:


	Number of Shares			Weighted Average Grant-Date Fair Value
Unvested, December 31, 2014		278		$	18.00
Granted		400,000			0.16
Vested		(173,658	)		0.21
Cancelled		—			—

Unvested, September 30, 2015		226,620		$	0.16

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Restatement of Condensed Consolidated Balance Sheets (Unaudited) (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Current Assets
Cash	$ 6,087,016	$ 141,944	$ 613,645	$ 48,589
Prepaid expenses and deposits	138,286	82,504
Total Assets	6,225,302	224,448
Current Liabilities
Accounts payable and accrued liabilities	874,628	693,362
Research agreement obligations	492,365	492,365
Derivative liability - warrants	32,196,000	9,415
Promissory notes	52,942	52,942
Total Current Liabilities	33,615,935	1,248,084
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 - 20,318,815)	62,891	20,319
Additional paid-in capital	104,402,206	85,265,776
Accumulated deficit	(131,855,730)	(86,309,731)
Total Stockholders' Deficit	(27,390,633)	(1,023,636)
Total LIABILITIES AND STOCKHOLDERS' DEFICIT	6,225,302	224,448
Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Series B Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
As Previously Reported [Member]
Current Assets
Cash	6,087,016	$ 141,944
Prepaid expenses and deposits	138,286
Total Assets	6,225,302
Current Liabilities
Accounts payable and accrued liabilities	874,628
Research agreement obligations	492,365
Derivative liability - warrants	7,426,684
Promissory notes	52,942
Total Current Liabilities	8,846,619
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Common stock, $0.001 par value, 500,000,000 shares authorized 32,638,811 shares issued and outstanding (2014 - 20,318,815)	62,891
Additional paid-in capital	100,568,900
Accumulated deficit	(103,253,108)
Total Stockholders' Deficit	(2,621,317)
Total LIABILITIES AND STOCKHOLDERS' DEFICIT	6,225,302
As Previously Reported [Member] \| Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
As Previously Reported [Member] \| Series B Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Adjustments [Member]
Current Liabilities
Derivative liability - warrants	24,769,316
Total Current Liabilities	24,769,316
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Additional paid-in capital	3,833,306
Accumulated deficit	(28,602,622)
Total Stockholders' Deficit	(24,769,316)
Adjustments [Member] \| Series A Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:
Adjustments [Member] \| Series B Preferred Stock [Member]
Stockholders' Equity (Deficit)
Convertible preferred stock, $0.001 par value - 10,000,000 shares authorized:

Restatement of Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (Detail) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001	$ 0.001
Common stock par value	$ 0.001	$ 0.001
Common stock shares authorized	500,000,000	500,000,000
Common stock shares issued	62,890,763	20,318,815
Common stock shares outstanding	62,890,763	20,318,815
Series A Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001	$ 0.001
Convertible preferred stock	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001	$ 0.001
Convertible preferred stock	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
As Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001
Convertible preferred stock	10,000,000
Common stock par value	$ 0.001
Common stock shares authorized	500,000,000
Common stock shares issued	32,638,811
Common stock shares outstanding	32,638,811
As Previously Reported [Member] \| Series A Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001
Preferred stock shares designated	1,250,000
Preferred stock issued	0
Preferred stock outstanding	0
As Previously Reported [Member] \| Series B Preferred Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Preferred stock par value	$ 0.001
Preferred stock shares designated	1,500,000
Preferred stock issued	0
Preferred stock outstanding	0

Restatement of Condensed Consolidated statements of Operation and Comprehensive Loss (Unaudited) (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating expenses:
General and administrative	$ 968,759	$ 1,351,209	$ 2,324,432	$ 2,899,181
Research and development	769,219	32,500	1,579,754	77,500
Loss from Operations	(1,737,978)	(1,383,709)	(3,904,186)	(2,976,681)
Other Income (Expense)
Changes in fair value of derivative liabilities	30,266,000	(74,062)	(28,485,585)	243,475
Foreign exchange			775
Shares issued in settlement agreement	(24,697)		(24,697)
Net Income (Loss) for the Period	28,503,325	(1,567,836)	(32,413,693)	(30,146,586)
Other comprehensive income
Foreign exchange translation adjustment	0	2,972	0	2,765
TOTAL COMPREHENSIVE INCOME (LOSS)	$ 28,503,325	$ (1,564,864)	$ (32,413,693)	$ (30,143,821)
Basic Net Income (Loss) per Share	$ 0.59	$ (0.09)	$ (0.88)	$ (2.27)
Diluted Net Income (Loss) per Share	$ 0.35	$ (0.09)	$ (0.88)	$ (2.27)
Weighted Average Number of Common Shares Outstanding, Basic	48,585,003	17,310,708	36,651,565	13,292,886
Weighted Average Number of Common Shares Outstanding, Diluted	80,944,993	17,310,708	36,651,565	13,292,886
As Previously Reported [Member]
Operating expenses:
General and administrative	$ 968,759		$ 2,324,432
Research and development	769,219		1,579,754
Loss from Operations	(1,737,978)		(3,904,186)
Other Income (Expense)
Changes in fair value of derivative liabilities	4,246,663		(4,759,269)
Foreign exchange			775
Inducement expense			(8,256,000)
Shares issued in settlement agreement	(24,697)		(24,697)
Net Income (Loss) for the Period	2,483,988		(16,943,377)
Other comprehensive income
Foreign exchange translation adjustment	0		0
TOTAL COMPREHENSIVE INCOME (LOSS)	$ 2,483,988		$ (16,943,377)
Basic Net Income (Loss) per Share	$ 0.05		$ (0.46)
Diluted Net Income (Loss) per Share	$ 0.03		$ (0.46)
Weighted Average Number of Common Shares Outstanding, Basic	48,585,003		36,651,565
Weighted Average Number of Common Shares Outstanding, Diluted	80,944,993		36,651,565
Adjustments [Member]
Other Income (Expense)
Changes in fair value of derivative liabilities	$ 26,019,337		$ (23,726,316)
Inducement expense			8,256,000
Net Income (Loss) for the Period	26,019,337		(15,470,316)
Other comprehensive income
Foreign exchange translation adjustment	0		0
TOTAL COMPREHENSIVE INCOME (LOSS)	$ 26,019,337		$ (15,470,316)
Basic Net Income (Loss) per Share	$ 0.54		$ (0.42)
Diluted Net Income (Loss) per Share	$ 0.32		$ (0.42)
Weighted Average Number of Common Shares Outstanding, Basic	48,585,003		36,651,565
Weighted Average Number of Common Shares Outstanding, Diluted	80,944,993		36,651,565

Restatement of Condensed Consolidated statements of Cash Flows (Unaudited) (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ 28,503,325	$ (1,567,836)	$ (32,413,693)	$ (30,146,586)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities			28,485,585	(243,475)
Loss on settlement agreement			24,697
Stock based compensation			261,805	1,265,625
Changes in operating assets and liabilities:
Prepaid expenses			(55,782)	(15,000)
Accounts payable and accrued liabilities			204,956	291,359
NET CASH USED IN OPERATING ACTIVITIES			(3,492,432)	(1,517,944)
CASH FLOWS FROM FINANCING ACTIVITIES
Private placement, net of finders' fee			2,326,014	2,097,500
Proceeds from exercise of warrants			7,427,998
Finders' fee on exercise of warrants			(316,508)	500
NET CASH PROVIDED BY FINANCING ACTIVITIES			9,437,504	2,083,000
INCREASE IN CASH			5,945,072	565,056
CASH, BEGINNING OF PERIOD			141,944	48,589
CASH, END OF PERIOD	6,087,016	$ 613,645	6,087,016	$ 613,645
As Previously Reported [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	2,483,988		(16,943,377)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities			4,759,269
Inducement expense			8,256,000
Loss on settlement agreement			24,697
Stock based compensation			261,805
Changes in operating assets and liabilities:
Prepaid expenses			(55,782)
Accounts payable and accrued liabilities			204,956
NET CASH USED IN OPERATING ACTIVITIES			(3,492,432)
CASH FLOWS FROM FINANCING ACTIVITIES
Private placement, net of finders' fee			2,009,506
Proceeds from exercise of warrants			7,427,998
NET CASH PROVIDED BY FINANCING ACTIVITIES			9,437,504
INCREASE IN CASH			5,945,072
CASH, BEGINNING OF PERIOD			141,944
CASH, END OF PERIOD	6,087,016		6,087,016
Adjustments [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ 26,019,337		(15,470,316)
Adjustments to reconcile net loss to net cash from operating activities:
Changes in fair value of derivative liabilities			23,726,316
Inducement expense			(8,256,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Private placement, net of finders' fee			316,508
Finders' fee on exercise of warrants			$ (316,508)

Net Income (Loss) Per Share (Detail) - USD ($)	3 Months Ended		9 Months Ended
Net Income (Loss) Per Share (Detail) - USD ($)	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Notes to Financial Statements
Net income (loss)	$ 28,503,325	$ (1,567,836)	$ (32,413,693)	$ (30,146,586)
Weighted average shares outstanding - basic	48,585,003	17,310,708	36,651,565	13,292,886
Common stock warrants	31,959,990
Common stock options	400,000
Weighted average shares outstanding - diluted	80,944,993	17,310,708	36,651,565	13,292,886
Net income (loss) per share data:
Basic	$ 0.59	$ (0.09)	$ (0.88)	$ (2.27)
Diluted	$ 0.35	$ (0.09)	$ (0.88)	$ (2.27)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (3) (Detail) - USD ($)	3 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Notes to Financial Statements
Strike price		$ 1.03
Volatility (annual)		199.00%
Risk-free rate		0.05%
Contractual term (years)		2 months 27 days
Dividend yield (per share)	0.00%	0.00%
Fair value of Conversion Option at extinguishment		$ 708,000

Capital Stock, As Restated (Narrative) (Detail)		1 Months Ended				3 Months Ended		9 Months Ended	12 Months Ended
Capital Stock, As Restated (Narrative) (Detail)	May 31, 2015 Warrant $ / shares	Aug. 31, 2015 USD ($) shares	Jul. 31, 2015 USD ($) shares	Mar. 31, 2015 USD ($) $ / Equity shares	Jan. 31, 2015 USD ($) $ / shares $ / Equity shares	Sep. 30, 2015 USD ($) $ / shares shares	Sep. 30, 2014	Sep. 30, 2015 USD ($) $ / shares shares	Dec. 31, 2014 $ / shares	Oct. 14, 2009 shares
Finders fee and issuance costs \| $								$ 316,508
Expected life								4 years 1 month 24 days
Risk free interest rate							0.05%
Contractual term								2 years 5 months 16 days
Volatility								141.00%
Risk free Rate								1.50%
Proceeds from warrants exercised \| $								$ 7,427,998
Stock options weighted average exercise price \| $ / shares								$ 0.54
Volatility rate							199.00%
Dividend yield						0.00%	0.00%
As Previously Reported [Member]
Proceeds from warrants exercised \| $								$ 7,427,998
Seriesa Warrant [Member]
Exercise price of warrants \| $ / shares	$ 0.10
Seriesa Warrant [Member] \| As Previously Reported [Member]
Exercise price of warrants \| $ / shares	1.50
Series B Warrant [Member]
Exercise price of warrants \| $ / shares	$ 0.20					$ 0.20		$ 0.20
Replacement of warrants \| Warrant	2
Number of warrants issued \| shares						12,320,000		12,320,000
Number of warrants exercised \| shares								24,639,995
Proceeds from warrants exercised \| $								$ 4,928,000
Series B Warrant [Member] \| As Previously Reported [Member]
Exercise price of warrants \| $ / shares	$ 0.40
Series C Warrant [Member]
Exercise price of warrants \| $ / shares	$ 0.50					$ 0.50		$ 0.50
Replacement of warrants \| Warrant	2
Number of warrants issued \| shares						12,320,000		12,320,000
Number of warrants exercised \| shares								5,000,000
Proceeds from warrants exercised \| $								$ 2,500,000
Series C Warrant [Member] \| As Previously Reported [Member]
Exercise price of warrants \| $ / shares	$ 1.00
Series B And C Warrants [Member]
Fair value of warrants \| $						$ 6,133,000		6,133,000
Stock Options [Member]
Stock options weighted average exercise price \| $ / shares
Warrant
Aggregate purchase price \| $								$ 9,313,000
Expected life								5 years
Volatility rate of stock options								158.00%
Risk free interest rate								1.20%
2014 Omnibus Stock Option Plan [Member]
Expected life								5 years
Risk free interest rate								1.54%
Stock options granted \| shares								400,000
Stock options weighted average exercise price \| $ / shares								$ 0.17
Stock options fair value \| $								$ 62,000
Stock option fair value per share \| $ / shares								$ 0.16
Volatility rate								155.00%
Dividend yield								0.00%
Share based compensation costs not yet recognized \| $						$ 21,000		$ 21,000
Share based compensation costs recognition period								1 year 4 months 24 days
Stock issued share based compensation, shares \| shares		50,000	118,450
Stock issued share based compensation \| $		$ 26,474	$ 21,913
2014 Omnibus Stock Option Plan [Member] \| Stock Options [Member]
Options issued to acquire common shares \| shares										10,000,000
Private Placement [Member]
Units issued \| shares				5,000,000	7,320,000
Sales price per unit \| $ / Equity				0.20	0.20
Aggregate purchase price \| $				$ 950,000	$ 1,250,000
Finders fee and issuance costs \| $				$ 50,000	$ 214,000
Number of common stock included in equity unit \| shares				1	1
Private Placement [Member] \| Seriesa Warrant [Member]
Number of securities callable by each warrant or right warrants \| shares				1	1
Exercise price of warrants \| $ / shares					$ 1.50
Warrant expiration period					5 years
Private Placement [Member] \| Series B Warrant [Member]
Number of securities callable by each warrant or right warrants \| shares				1	1
Exercise price of warrants \| $ / shares					$ 0.40
Warrant expiration period					6 months
Private Placement [Member] \| Series C Warrant [Member]
Number of securities callable by each warrant or right warrants \| shares				1	1
Exercise price of warrants \| $ / shares					$ 1.00
Warrant expiration period					5 years
Private Placement [Member] \| Series D Warrant [Member]
Number of securities callable by each warrant or right warrants \| shares				1	1
Exercise price of warrants \| $ / shares					$ 0.75
Warrant expiration period					5 years
Private Placement [Member] \| Series E Warrant [Member]
Number of securities callable by each warrant or right warrants \| shares				1	1
Exercise price of warrants \| $ / shares					$ 1.25
Warrant expiration period					5 years
Private Placement [Member] \| Subsequent Warrant Issuance [Member]
Class of warrant or right, number of securities called by warrants or rights \| shares				125,000	366,000

CAPITAL STOCK (1) (Detail)	9 Months Ended
CAPITAL STOCK (1) (Detail)	Sep. 30, 2015 $ / shares shares
Number of Warrants
Balance, December 31, 2014 \| shares	2,659,417
Issued \| shares	86,730,975
Exercised \| shares	(29,639,995)
Extinguished or expired \| shares	(203,900)
Balance, September 30, 2015 \| shares	59,546,497
Weighted Average Exercise Price
Beginning Balance \| $ / shares	$ 1.83
Issued \| $ / shares	0.54
Exercised \| $ / shares	0.25
Extinguished or expired \| $ / shares	2.39
Balance, September 30, 2015 \| $ / shares	$ 0.68
Weighted Average Remaining Life
Balance, December 31, 2014	4 years 1 month 24 days
Issued	4 years 6 months 7 days
Balance, September 30, 2015	4 years 5 months 19 days

CAPITAL STOCK ( 2) (Detail) - USD ($)	3 Months Ended	9 Months Ended	12 Months Ended
CAPITAL STOCK ( 2) (Detail) - USD ($)	Sep. 30, 2014	Sep. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Issued		86,730,975
Issued		$ 0.54
Outstanding at January 1, 2014	2 months 27 days
Stock Options [Member]
Balance, December 31, 2014		65,430	65,430
Issued		$ 0.17
Issued		400,000
Cancelled/Forfeited			0
Balance, December 31, 2014		465,430	65,430	65,430
Balance, December 31, 2014		$ 18.00	$ 18.00
Exercisable at September 30, 2015		238,810
Issued
Cancelled/Forfeited
Balance, December 31, 2014		2.62	$ 18.00	$ 18.00
Exercisable at September 30, 2015		$ 5.00
Outstanding at January 1, 2014		4 years 2 months 23 days	4 years 15 days	5 years 5 days
Exercisable at September 30, 2015		4 years 1 month 2 days
Issued			4 years 4 months 21 days
Outstanding at September 30, 2015		$ 182,000
Issued			$ 182,000
Exercisable at September 30, 2015		$ 80,000

Subsequent Events - Additional Information (Detail) - USD ($)		1 Months Ended	9 Months Ended
	Nov. 12, 2015	Nov. 10, 2015	Sep. 30, 2015	Nov. 06, 2015	Dec. 31, 2014
Subsequent Event [Line Items]
Award of stock options to purchase			59,546,497		2,659,417
Proceeds from warrant exercised			$ 7,427,998
Series C Warrant [Member]
Subsequent Event [Line Items]
Proceeds from warrant exercised			$ 2,500,000
Omnibus Stock Plan [Member]
Subsequent Event [Line Items]
Number of shares reserved for issuance under the Plan			5,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Exercise price	$ 0.605
Options, terms	10 years
Subsequent Event [Member] \| Employees And Consultants [Member]
Subsequent Event [Line Items]
Number of options approved	690,000
Number of vested options	290,000
Subsequent Event [Member] \| Series C Warrant [Member]
Subsequent Event [Line Items]
Number of warrant exercised		1,728,000
Proceeds from warrant exercised		$ 864,000
Subsequent Event [Member] \| Minimum [Member]
Subsequent Event [Line Items]
Vesting period	1 year
Subsequent Event [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Vesting period	3 years
Subsequent Event [Member] \| Chief Executive Officer, President [Member]
Subsequent Event [Line Items]
Annual base salary	$ 280,000
Performance-based bonus ranging	50.00%
Shares of unregistered common stock	315,000
Award of stock options to purchase	2,000,000
Exercise price	$ 0.605
Common stock, vest	1,000,000
Stock options vesting period	24 months
Subsequent Event [Member] \| Director [Member] \| Sherry Grisewood [Member]
Subsequent Event [Line Items]
Number of options approved	150,000
Subsequent Event [Member] \| Director [Member] \| Mark Reddish [Member]
Subsequent Event [Line Items]
Number of options approved	150,000
Subsequent Event [Member] \| Omnibus Stock Plan [Member]
Subsequent Event [Line Items]
Number of shares reserved for issuance under the Plan				7,000,000

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) AS RESTATED (Parenthetical)	9 Months Ended
	Sep. 30, 2015 USD ($)
Statement of Stockholders' Equity [Abstract]
Net of finders' fee	$ 140,000

NATURE OF OPERATIONS	9 Months Ended
NATURE OF OPERATIONS	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NOTE 1: NATURE OF OPERATIONS TapImmune Inc. (the “Company”), a Nevada corporation incorporated in 1992, is a biotechnology Company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune’s approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2: BASIS OF PRESENTATION The accompanying unaudited condensed financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. The condensed consolidated balance sheet as of September 30, 2015, condensed consolidated statements of interim financials include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The results for the statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2015 or for any future interim period. The condensed balance sheet at December 31, 2014 has been derived from audited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2014, and notes thereto included in the Company’s annual report on Form 10-K.

LIQUIDITY AND FINANCIAL CONDITION	9 Months Ended
LIQUIDITY AND FINANCIAL CONDITION	Sep. 30, 2015
Text Block [Abstract]
LIQUIDITY AND FINANCIAL CONDITION	NOTE 3: LIQUIDITY AND FINANCIAL CONDITION The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales. As of September 30, 2015, the Company had cash and cash equivalents of approximately $6,087,000. Historically, the Company has net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 4: SIGNIFICANT ACCOUNTING POLICIES There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on April 15, 2015. *Prior Period Reclassifications* The expense categories of the comparable prior period have been reclassified for comparability with the September 30, 2015 presentation. These reclassifications had no effect on previously reported net loss.

PROMISSORY NOTES, RELATED PARTY	9 Months Ended
PROMISSORY NOTES, RELATED PARTY	Sep. 30, 2015
Text Block [Abstract]
PROMISSORY NOTES, RELATED PARTY	NOTE 7: PROMISSORY NOTES, RELATED PARTY The Company has outstanding promissory notes in the amount of $52,942 (December 31, 2014 - $52,942), of which $23,000 of promissory notes relate to amounts owed to an officer and a director of the Company. The promissory notes bear no interest charges and have no fixed repayment terms.

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9: SUBSEQUENT EVENTS 1. On November 6, 2015, the Board of Directors approved an amendment to the Company’s 2014 Omnibus Stock Ownership Plan which provided for an increase in the number of shares reserved for issuance under the Plan by 5 million shares to 7 million shares. 2. On November 12, 2015, the Company entered into a new employment agreement with Dr. Glynn Wilson, the Company’s Chief Executive Officer, President and Chairman. The initial term of the agreement ends November 11, 2017, but it will automatically be extended for 12-months unless terminated by the Company or Dr. Wilson by written notice to the other not later than 12 months prior to the end of such initial term. It will thereafter be further extended for an additional 12 months after the end of each such extended term unless terminated by the Company or Dr. Wilson by written notice no later than 90 days prior to the end of such term, subject to early termination for cause or good reason by Dr. Wilson. Under the agreement, Dr. Wilson’s annual base salary is to be $280,000, and he is entitled to a performance-based bonus ranging of up to 50% of his base salary based on goals and other conditions as the Board determines on an annual basis, which may be paid in cash or equity awards as the Board determines. In connection with entering into the new agreement, Dr. Wilson will receive equity awards under the Company’s 2014 Omnibus Stock Ownership Plan consisting of (i) an award of 315,000 shares of unregistered common stock, which immediately vest, and (ii) an award of stock options to purchase 2 million shares of Company common stock, prior to November 12, 2025, for $0.605 per share (the closing price of the common stock on November 12, 2015). One-half of the stock options will be immediately vested, and the remaining 1 million shares will vest ratably over the following 24 months. 3. On November 12, 2015, the Board of Directors approved awards of stock options to acquire 150,000 shares of common stock to each of Sherry Grisewood and Mark Reddish. All of such options are fully vested. In addition, the Board approved awards of stock options to four individuals (two employees and two consultants) to purchase an aggregate of 690,000 shares of common stock. Of the options granted to the employees and consultants, 290,000 are immediately vested, and the remainder vest over periods of between one and three years. All of the stock options have a 10-year term, and the exercise price is $0.605 per share, the closing price of the common stock on the date of grant. 5. Between October 1 and November 10, 2015, holders of the Series C Warrants exercised 1,728,000 of Series C Warrants registered under our recent registration statements on Form S-1, resulting in proceeds of $864,000 to the Company.

Liquidity and Financial Condition (Narrative) (Detail)	Sep. 30, 2015 USD ($)
Liquidity And Financial Condition Details Narrtive
Cash and cash equivalents	$ 6,087,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (1) (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Derivative liability - warrants	$ 32,196,000	$ 9,000
Total	32,196,000	9,000
Carrying Value [Member]
Derivative liability - warrants	32,196,000
Total	32,196,000
Fair Value, Inputs, Level 1 [Member]
Derivative liability - warrants
Total
Fair Value, Inputs, Level 2 [Member]
Derivative liability - warrants
Total
Fair Value, Inputs, Level 3 [Member]
Derivative liability - warrants	32,196,000	9,000
Total	$ 32,196,000	9,000
Fair Value [Member]
Derivative liability - warrants		9,000
Total		$ 9,000

DERIVATIVE LIABILITY - WARRANTS AND DERIVATIVE LIABILITY - CONVERSION OPTION (2) (Detail)	9 Months Ended
	Sep. 30, 2015 USD ($)
Notes to Financial Statements
Beginning Balance	$ 9,000
Additions during the quarter	15,446,000
Exercise of warrants	(11,745,000)
Change in fair value of warrant liability	28,486,000
Ending Balance	$ 32,196,000

PROMISSORY NOTES, RELATED PARTY (Detail) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Notes to Financial Statements
Outstanding promissory notes		$ 52,942
Promissory notes officer and a director	$ 23,000

CAPITAL STOCK ( 3) (Detail)	9 Months Ended
CAPITAL STOCK ( 3) (Detail)	Sep. 30, 2015 $ / shares shares
Granted	86,730,975
Unvested Options [Member]
Unvested, December 31, 2014	278
Granted	400,000
Vested	(173,658)
Cancelled	0
Unvested, September 30, 2015	226,620
Weighted Average Grant-Date Fair Value
Unvested, December 31, 2014 \| $ / shares	$ 18.00
Granted \| $ / shares	0.16
Vested \| $ / shares	0.21
Cancelled \| $ / shares	0
Unvested, September 30, 2015 \| $ / shares	$ 0.16